Latest News
Enbridge's C$4B Sunrise Pipeline Gets Federal Go-Ahead
Enbridge secures Canadian approval for its C$4 billion Sunrise Expansion, adding 300 million cubic feet per day of gas capacity and supporting LNG exports.
Greg Abel Takes the Helm at Berkshire Hathaway's Annual Meeting
Greg Abel will lead Berkshire Hathaway's annual meeting on May 2, facing investor scrutiny over the company's $373B cash pile and underperformance.
Enterprise Products Partners Prepares for Earnings and Distribution Payout
Enterprise Products Partners (EPD) closed at $38.00 ahead of first-quarter earnings on Tuesday and a $0.55 per-unit distribution on May 14. Analysts expect EPS of $0.71.
Coca-Cola Earnings Preview: World Cup Push and Resilient Latin American Volumes in Focus
Coca-Cola reports Q1 earnings April 28, with a new World Cup campaign and strong Latin American bottler volumes offering hope for demand after years of price hikes.
3M Stock Edges Higher After Q1 Earnings Beat, Holds 2026 Guidance Despite Oil Headwinds
3M shares rose 0.79% after Q1 adjusted earnings beat estimates. The company maintained its 2026 guidance despite a $125 million annual oil-cost hit.
UEC Stock Drops 6% as Burke Hollow Mine Faces Production Scrutiny
Uranium Energy Corp. shares slid 6% to $14.05 as investors shift focus to production execution at its new Burke Hollow mine, with the broader uranium sector also declining.
SiriusXM and iHeartMedia in Early Merger Talks That Could Reshape Audio Landscape
SiriusXM and iHeartMedia are in early-stage merger discussions, Bloomberg reported. A tie-up would create a $12 billion audio powerhouse, combining satellite, broadcast, and podcast assets.
Guggenheim Initiates Buy on Shake Shack Ahead of Q1 Earnings
Guggenheim initiated Shake Shack at Buy with a $120 target, boosting shares 5.6%. The call comes before May 7 earnings, with Q1 visits up nearly 20%.
CRISPR Therapeutics Shares Slide 11.6% as Casgevy Faces Revenue Test
CRISPR Therapeutics shares fell 11.6% Friday as investors weigh Casgevy's market performance and upcoming governance decisions.
Intellia Shares Surge on Eve of Historic CRISPR Phase 3 Data Release
Intellia Therapeutics shares rallied 19.3% after hours Friday as investors await Phase 3 data from its HAELO trial of lonvoguran ziclumeran, an in vivo CRISPR gene-editing therapy for hereditary angioedema.